

Bomi Italia S.p.A.

– PRESS RELEASE –

Bomi Group: principal economic-financial results for the year ended 31 December 2017 reveal significant growth

- **Consolidated value of production** of **Euro 117.8 million** (+17% compared to 31.12.2016)
- **Consolidated Gross Operating Margin (EBITDA)** of **Euro 11 million** (representing a margin of 9.4% on the consolidated value of production at 31 December 2017), net of extraordinary and non-recurring items, **an increase of 27%** (Euro 8.7 million at 31.12.2016)
- **Consolidated Net Profit** of **Euro 2.7 million** representing an increase of **91%** compared to 31 December 2016, of which **Net profit attributable to Bomi Group** was **Euro 2 million** representing an increase of 349% compared to 31 December 2016

Vaprio d'Adda, 22 March 2018

Bomi Italia, Bomi Italia S.p.A. ("**Bomi**" or the "**Company**" or the "**Issuer**") the parent company of Bomi Group, a market leader in the biomedical logistics sector and the management of high technology healthcare products, which is listed on the multilateral trading system of **AIM Italia / Mercato Alternativo del Capitale Capitale**, organised and managed by Borsa Italiana S.p.A., announces that the Board of Directors has examined the principal consolidated results for the year to 31 December 2017. These confirm the growth trend of the Bomi Group, which in 2017 achieved significant synergies and rationalised the Group structure to support profitability, and obtained significant results that are higher than the projected Business Plan estimates and which are shown below.

Principal economic-financial results for the year ended 31 December 2017

Consolidated value of production was **Euro 117.8 million**, representing **an increase of 17%** compared to the Euro 100 million reported in 2016, due to internal growth (accounting for about 12%) and a positive exchange rate effect (of about 3%), as well as the inclusion in the consolidation area of new companies – Espadist, the Mexican company acquired in the second half of 2017 and Faro Srl, the transport company based in Bari, acquired in March 2017. The **consolidated value of production** at constant euro/foreign currency exchange rates, was in line with the projections in the Group's business plan ("the Plan") 2017 – 2019 approved and published on 8 May 2017.

The **consolidated gross operating margin (EBITDA)** was **Euro 11 million** (representing a margin of about 9.4% on the consolidated value of production for the year to 31 December 2017), net of extraordinary and non-recurring items, representing **an increase of about 27%** compared to Euro 8.7 million reported in 2016 (representing a margin of about 8.7% on the consolidated value of production for the year to 31 December 2016). The **consolidated EBITDA** for the year to 31 December 2017 is **higher than the projected consolidated EBITDA estimate in the Plan 2017 – 2019** by about 4% (equal to 9% at constant euro/foreign currency exchange rates).



Consolidated net profit was **Euro 2.7 million**, of which **Euro 2 million is consolidated net profit attributable to the Group**, representing **90% growth in net profit** and **an increase in Group net profit of 349%** compared to 31 December 2016. **The group profit is 58% higher than the forecasts in the Plan 2017 – 2019** (equal to **77% at constant euro/foreign currency exchange rates**).

The **Consolidated net financial position (NFP)** is **Euro 25.5 million** compared to Euro 15.9 million at 31 December 2016. The difference in the NFP is mainly due to the acquisition of the minority interest in the Brazilian subsidiary in November 2017 for a total consideration of Euro 15.6 million (including price and extraordinary dividend payment). It should be noted that the shareholdings of Simest in the subsidiaries in Brazil, Mexico and Chile (the latter was already present at 31.12.2016), equal to a total of Euro 6.6 million, appear in the consolidated financial statements as non-controlling interests.

It should be noted that the accounting data shown in the present communication have not been subjected to an independent audit and it should also be noted that the preliminary parent company and consolidated financial statements of the Group for the year ended 31 December 2017 which are subject to independent audit, will be submitted for the approval of the Board of Directors at its next meeting on 29 March 2018, as scheduled in the financial calendar.

Bomi Italia S.p.A. is the Parent Company of Bomi Group, a world leader in the biomedical logistics sector and in the management of high technology healthcare products. It was one of the first companies to receive the "Elite" certificate issued by Borsa Italiana.

Bomi Group's activities are concentrated in the integrated logistics sector and offer a wide range of logistics services in outsourcing to companies operating in the healthcare sector, managing distribution of medical equipment, pharmaceuticals, in-vitro diagnostic equipment, reagents and implant products.

Bomi Group's portfolio of about 100 clients includes some of the world's top healthcare companies (such as the leading pharmaceutical companies and producers of healthcare devices) as well as small and medium sized companies operating at a global level in the biomedical, diagnostics and biotech industries.

Bomi Group currently has about 1,080 employees and operates through subsidiary companies and associated companies in Europe, South America, China and the United States and its services are also provided, through strategic alliances with local partners.

ISIN Ordinary Share Code: IT0005108748 – Ordinary Share Ticker: BOMI

ISIN Convertible Bond Code: IT0005114480 – Convertible Bond Ticker: BOMI20

For further information.

• **Bomi Italia S.p.A.** •

Investor Relator
tel: +3903962781313
e.mail: investorrelator@bomigroup.com

• **BPER Banca S.p.A.** •

Nominated Adviser
tel: +390512756537
e.mail: bomi@bper.it

